vs
HELEN OF TROY LTD（HELE）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是HELEN OF TROY LTD的1.5倍（$772.1M vs $512.8M），Revvity净利率更高（12.7% vs -16.4%，领先29.1%），Revvity同比增速更快（5.9% vs -3.4%），Revvity自由现金流更多（$161.8M vs $5.8M），过去两年Revvity的营收复合增速更高（9.0% vs 2.4%）
海伦特洛伊是美国上市企业，主营自有及授权品牌家居用品、健康家居用品与美容产品的设计研发和全球营销，旗下拥有OXO International、Kaz等多家子公司。公司注册总部设于百慕大汉密尔顿，美国运营总部位于得克萨斯州埃尔帕索，公司名称源自古希腊神话人物特洛伊海伦。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HELE vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.5倍
$512.8M
营收增速更快
RVTY
高出9.2%
-3.4%
净利率更高
RVTY
高出29.1%
-16.4%
自由现金流更多
RVTY
多$156.0M
$5.8M
两年增速更快
RVTY
近两年复合增速
2.4%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $512.8M | $772.1M |
| 净利润 | $-84.1M | $98.4M |
| 毛利率 | 46.9% | — |
| 营业利润率 | -1.6% | 14.5% |
| 净利率 | -16.4% | 12.7% |
| 营收同比 | -3.4% | 5.9% |
| 净利润同比 | -269.4% | 3.9% |
| 每股收益（稀释后） | $-3.65 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HELERVTY
| Q4 25 | $512.8M | $772.1M | ||
| Q3 25 | $431.8M | $698.9M | ||
| Q2 25 | $371.7M | $720.3M | ||
| Q1 25 | $485.9M | $664.8M | ||
| Q4 24 | $530.7M | $729.4M | ||
| Q3 24 | $474.2M | $684.0M | ||
| Q2 24 | $416.8M | $691.7M | ||
| Q1 24 | $489.2M | $649.9M |
净利润HELERVTY
| Q4 25 | $-84.1M | $98.4M | ||
| Q3 25 | $-308.6M | $46.7M | ||
| Q2 25 | $-450.7M | $53.9M | ||
| Q1 25 | $50.9M | $42.2M | ||
| Q4 24 | $49.6M | $94.6M | ||
| Q3 24 | $17.0M | $94.4M | ||
| Q2 24 | $6.2M | $55.4M | ||
| Q1 24 | $42.7M | $26.0M |
毛利率HELERVTY
| Q4 25 | 46.9% | — | ||
| Q3 25 | 44.2% | 53.6% | ||
| Q2 25 | 47.1% | 54.5% | ||
| Q1 25 | 48.6% | 56.5% | ||
| Q4 24 | 48.9% | — | ||
| Q3 24 | 45.6% | 56.3% | ||
| Q2 24 | 48.7% | 55.7% | ||
| Q1 24 | 49.0% | 54.6% |
营业利润率HELERVTY
| Q4 25 | -1.6% | 14.5% | ||
| Q3 25 | -73.1% | 11.7% | ||
| Q2 25 | -109.5% | 12.6% | ||
| Q1 25 | 0.4% | 10.9% | ||
| Q4 24 | 14.2% | 16.3% | ||
| Q3 24 | 7.3% | 14.3% | ||
| Q2 24 | 7.4% | 12.4% | ||
| Q1 24 | 13.5% | 6.8% |
净利率HELERVTY
| Q4 25 | -16.4% | 12.7% | ||
| Q3 25 | -71.5% | 6.7% | ||
| Q2 25 | -121.3% | 7.5% | ||
| Q1 25 | 10.5% | 6.4% | ||
| Q4 24 | 9.3% | 13.0% | ||
| Q3 24 | 3.6% | 13.8% | ||
| Q2 24 | 1.5% | 8.0% | ||
| Q1 24 | 8.7% | 4.0% |
每股收益（稀释后）HELERVTY
| Q4 25 | $-3.65 | $0.86 | ||
| Q3 25 | $-13.44 | $0.40 | ||
| Q2 25 | $-19.65 | $0.46 | ||
| Q1 25 | $2.20 | $0.35 | ||
| Q4 24 | $2.17 | $0.77 | ||
| Q3 24 | $0.74 | $0.77 | ||
| Q2 24 | $0.26 | $0.45 | ||
| Q1 24 | $1.76 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $27.1M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $852.3M | $7.3B |
| 总资产 | $2.3B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HELERVTY
| Q4 25 | $27.1M | $919.9M | ||
| Q3 25 | $22.4M | $931.4M | ||
| Q2 25 | $22.7M | $991.8M | ||
| Q1 25 | $18.9M | $1.1B | ||
| Q4 24 | $40.8M | $1.2B | ||
| Q3 24 | $20.1M | $1.2B | ||
| Q2 24 | $16.1M | $2.0B | ||
| Q1 24 | $18.5M | $1.7B |
总债务HELERVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $921.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $672.0M | — |
股东权益HELERVTY
| Q4 25 | $852.3M | $7.3B | ||
| Q3 25 | $926.3M | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.7B | $7.6B | ||
| Q4 24 | $1.6B | $7.7B | ||
| Q3 24 | $1.6B | $7.9B | ||
| Q2 24 | $1.5B | $7.9B | ||
| Q1 24 | $1.6B | $7.8B |
总资产HELERVTY
| Q4 25 | $2.3B | $12.2B | ||
| Q3 25 | $2.4B | $12.1B | ||
| Q2 25 | $2.7B | $12.4B | ||
| Q1 25 | $3.1B | $12.4B | ||
| Q4 24 | $3.0B | $12.4B | ||
| Q3 24 | $2.9B | $12.8B | ||
| Q2 24 | $2.8B | $13.4B | ||
| Q1 24 | $2.8B | $13.4B |
负债/权益比HELERVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.41× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $5.8M | $161.8M |
| 自由现金流率自由现金流/营收 | 1.1% | 21.0% |
| 资本支出强度资本支出/营收 | 1.2% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $55.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流HELERVTY
| Q4 25 | $11.9M | $182.0M | ||
| Q3 25 | $-10.5M | $138.5M | ||
| Q2 25 | $58.3M | $134.3M | ||
| Q1 25 | $35.0M | $128.2M | ||
| Q4 24 | $8.3M | $174.2M | ||
| Q3 24 | $44.6M | $147.9M | ||
| Q2 24 | $25.3M | $158.6M | ||
| Q1 24 | $73.6M | $147.6M |
自由现金流HELERVTY
| Q4 25 | $5.8M | $161.8M | ||
| Q3 25 | $-21.9M | $120.0M | ||
| Q2 25 | $45.0M | $115.5M | ||
| Q1 25 | $27.1M | $112.2M | ||
| Q4 24 | $191.0K | $149.8M | ||
| Q3 24 | $39.7M | $125.6M | ||
| Q2 24 | $16.2M | $136.6M | ||
| Q1 24 | $66.6M | $129.7M |
自由现金流率HELERVTY
| Q4 25 | 1.1% | 21.0% | ||
| Q3 25 | -5.1% | 17.2% | ||
| Q2 25 | 12.1% | 16.0% | ||
| Q1 25 | 5.6% | 16.9% | ||
| Q4 24 | 0.0% | 20.5% | ||
| Q3 24 | 8.4% | 18.4% | ||
| Q2 24 | 3.9% | 19.7% | ||
| Q1 24 | 13.6% | 20.0% |
资本支出强度HELERVTY
| Q4 25 | 1.2% | 2.6% | ||
| Q3 25 | 2.7% | 2.6% | ||
| Q2 25 | 3.6% | 2.6% | ||
| Q1 25 | 1.6% | 2.4% | ||
| Q4 24 | 1.5% | 3.4% | ||
| Q3 24 | 1.0% | 3.3% | ||
| Q2 24 | 2.2% | 3.2% | ||
| Q1 24 | 1.4% | 2.7% |
现金转化率HELERVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | 0.69× | 3.03× | ||
| Q4 24 | 0.17× | 1.84× | ||
| Q3 24 | 2.62× | 1.57× | ||
| Q2 24 | 4.08× | 2.87× | ||
| Q1 24 | 1.72× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HELE
| Beauty Wellness | $283.2M | 55% |
| Home Outdoor | $229.6M | 45% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
